Gene editing has been one of the finest inventions in the biotech domain that aims at structurally understanding a gene formation and mechanism, by further offering alteration Alzheimer’s disease is a progressive brain disorder that gradually affects the memory and relative brain functioning of the patient. Primarily described by dementia, Alzheimer’s disease generally affects the geriatric populace wherein the chances of memory loss are quite higher and apparent as a part of aging. Talking about the signs of this disease it also affects the cognitive skills, which further leads to inability to perform the routine tasks.
A gene has been found that can naturally lessen these symptoms of Alzheimer’s disease in human brain cells. This was discovered in a research conducted at Queen Mary University of London. The researchers have also designed a new drug-screening system so as to rapidly treat the disease. More than just the after treatment plan, it also successfully helps in preventing the disease symptoms.
To believe the numbers and facts provided by the Alzheimer’s Association, the disease is one the leading causes of fatalities in the US caused due to similar fatal diseases such as after cancer and CVDs and others. The figure estimation was 5.8 million of the Americans aging 65 years and above are currently (in 2020) fighting with the Alzheimer’s disease. This further creates the need of an innovative solution that not only aims at cure of the disease but at the same time works for its prevention. Thus, the early preventative drug testing platform designed by the researchers at Queen Mary University of London is seem to be the new boon for potential. The key challenge in examining the Alzheimer’s drugs for clinical trials is that participants need to have symptoms. But once people have symptoms, it is usually too late for treatments to have a significant effect, as many brain cells have already died.
